Literature DB >> 19545653

Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution.

Barry D Kahan1.   

Abstract

With surgical tools in place, increased knowledge concerning immunogenetics and alloimmunity as well as improved management of immunocompromised patients, the foundations were lain for the rapid development of the transplantation enterprise. In contrast to pre-transplant conditioning by thoracic duct drainage or total lymphoid irradiation, which were too cumbersome for routine execution among the burgeoning recipient pool, cyclosporine was a facile method to produce immunosuppression de novo after transplantation. On the one hand, clinical data confirmed the potency of cyclosporine in a variety of clinical settings. On the other hand, a pleiotropic array of side effects, particularly nephrotoxicity, beclouded the regimens, even when used in reduced doses in combination with azathioprine or together with rigorous individualization of therapy by concentration control. The advent of cyclosporine condemned conditioning by pretransplant blood transfusions and donor-recipient HLA matching to therapeutic obsolescence. However, cross-matching achieved greater significance particularly due to the development of flow cytometry methods to detect modest amounts of anti-donor antibody. Adjunctive treatments with polyclonal preparations or monoclonal antibodies were developed to provide an additional layer of security during the critical induction phase of immunosuppression and for treatment of rejection episodes refractory to high dose steroid therapy. Active immunologic investigation was stimulated by antibodies that discriminated CD4+ versus CD8+ T cells, leading to dissection of their numbers of precursors or mature elements as well as their distinct activities. The search for methods to induce, maintain and detect the state of transplantation tolerance continued. The encouraging results in clinical transplantation raised a variety of ethical concerns related to public attitudes; to retrieval, distribution, and allocation of the limited supply of deceased donor organs; the increased utilization of living persons; the opportunities for commerce; the quasi-righteous requests for organ gifts by unrelated individuals and the scant financial resources for long-term treatment with costly immunosuppression. Transplantation had now achieved its rightful place in the clinical armamentarium.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545653     DOI: 10.1016/j.transproceed.2009.05.001

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  9 in total

1.  Expanding the limits of isonitrile-mediated amidations: on the remarkable stereosubtleties of macrolactam formation from synthetic seco-cyclosporins.

Authors:  Xiangyang Wu; Jennifer L Stockdill; Peter K Park; Samuel J Danishefsky
Journal:  J Am Chem Soc       Date:  2012-01-17       Impact factor: 15.419

Review 2.  Transplantation immunology: solid organ and bone marrow.

Authors:  Javier Chinen; Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

3.  Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.

Authors:  Florian Rothweiler; Martin Michaelis; Peter Brauer; Jürgen Otte; Kristoffer Weber; Boris Fehse; Hans Wilhelm Doerr; Michael Wiese; Jörg Kreuter; Yousef Al-Abed; Ferdinando Nicoletti; Jindrich Cinatl
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  Selective clinical and immune response of the oligoclonal autoreactive T cells in Omenn patients after cyclosporin A treatment.

Authors:  A Lev; A J Simon; N Amariglio; G Rechavi; R Somech
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

5.  Effects of embryonic cyclosporine exposures on brain development and behavior.

Authors:  Danielle E Clift; Robert J Thorn; Emily A Passarelli; Mrinal Kapoor; Mary K LoPiccolo; Holly A Richendrfer; Ruth M Colwill; Robbert Creton
Journal:  Behav Brain Res       Date:  2015-01-13       Impact factor: 3.332

6.  Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model.

Authors:  Rashade A H Haynes; Evan Ware; Christopher Premanandan; Bevin Zimmerman; Lianbo Yu; Andrew J Phipps; Michael D Lairmore
Journal:  Blood       Date:  2009-11-20       Impact factor: 22.113

7.  Effects of converting tacrolimus formulation from twice-daily to once-daily in liver transplantation recipients.

Authors:  Ashok Thorat; Hong-Shiue Chou; Chen-Fang Lee; Ruey-Shyang Soong; Tsung-Han Wu; Chih-Hsien Cheng; Ting-Jung Wu; Kun-Ming Chan; Wei-Chen Lee
Journal:  Biomed Res Int       Date:  2014-07-14       Impact factor: 3.411

Review 8.  Mu-conotoxins as leads in the development of new analgesics.

Authors:  Raymond S Norton
Journal:  Molecules       Date:  2010-04-19       Impact factor: 4.411

9.  Halofuginone Synergistically Enhances Anti-Proliferation of Rapamycin in T Cells and Reduces Cytotoxicity of Cyclosporine in Cultured Renal Tubular Epithelial Cells.

Authors:  Tony L H Chu; Qiunong Guan; Christopher Y C Nguan; Caigan Du
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.